LathamTECH in Focus: How Should Crypto Companies Be Thinking About New Laws?
Regulatory Rollback: Impact on Industry of CFPB's Withdrawal of Fair Lending and UDAAP Informal Guidance — The Consumer Finance Podcast
The LathamTECH Podcast — Where Digital Assets Slot Into a Shifting Fintech Regulatory Landscape: Insights From the US, UK, and EU
The fatal flaws in the 2023 CRA rule
Everything Compliance: Shout Outs and Rants - Episode 154
Daily Compliance News: May 16, 2025, The Ethics Nightmare Edition
New York State Restaurant Reservation Anti-Piracy Act Cracks Down on a "Leech Industry"
Consumer Finance Monitor Podcast Episode: The Impact of the Election on the FTC
Compliance Tip of the Day: Standing at the Turning Point
Federal Court Strikes Down FDA Rule on LDTs - Thought Leaders in Health Law®
AI Legislation: The Statewide Spotlight — The Consumer Finance Podcast
100 Days In: What Employers Need to Know - Employment Law This Week® - #WorkforceWednesday®
Breaking Down the Shifting Vaccine Policy Landscape – Diagnosing Health Care Video Podcast
Fair Lending Shake-Ups: CFPB Vacates Townstone Settlement, FHFA Ends GSEs' Special Purpose Credit Programs — The Consumer Finance Podcast
Brooklyn District Attorney Eric Gonzalez – Innovative Approach to Safety
Exploring the Administration's Regulatory Impact on Private Equity — PE Pathways Podcast
Aligning Business Goals with Legal Strategies Amid Regulatory Change – Speaking of Litigation Video Podcast
Shifting Gears: Adapting to Regulatory Changes in Auto Finance — Moving the Metal: The Auto Finance Podcast
Podcast - Hot Topics in FDA Regulation: GLP-1s, LDTs, AI and More
Consumer Finance Monitor Podcast Episode: Everything You Want to Know About the CFPB as Things Stand Today, and Lots More - Part 2
WHAT’S ON THE AUSTRALIAN REGULATORY HORIZON? In this publication, we provide an overview of certain upcoming changes for private equity funds and their investors (both Australian and foreign) investing in Australia....more
India’s capital markets have experienced a significant surge in initial public offering (IPO) activity in 2024, positioning the country as a global leader in public offerings. With 327 IPOs raising approximately USD19.9...more
As the Trump administration’s antitrust landscape continues to develop, companies should stay alert to key changes in merger filing requirements, remedy expectations, agency personnel, and more. Signs indicate we are entering...more
The federal premerger notification program administered under the Hart-Scott-Rodino (HSR) Act recorded just 89 transactions in March 2025, marking the lowest monthly filing total in nearly five years. This downturn is the...more
With companies constantly developing new therapies and technologies, the biotech industry is a hotbed of innovation. This dynamic environment often leads to mergers and acquisitions (M&A) as a vehicle for larger companies to...more
Despite initial expectations for a strong rebound in M&A activity driven by pent-up demand, private equity managers saw a slower recovery in 2024 than initially expected, with improvement in the latter half of the year....more
The heightened focus on antitrust and competition issues that has defined dealmaking globally over the past few years looks set for readjustment since President Trump re-entered the White House. Under the Biden...more
Australian M&A defied a slow growth environment to post a solid performance in 2024, while dealmakers are optimistic about the prospects for the year ahead - Australia’s economy continues to grow at a slow pace as...more
As the global markets look towards 2025, a dynamic evolution is anticipated within the landscape of mergers and acquisitions (M&A). Key strategic drivers such as regulatory adjustments, monetary policy normalizations, and...more
This newsletter is a summary of the antitrust developments we think are most interesting to your business. Thomas Masterman, partner based in London, is our editor this month. He has selected: Out now: our latest global...more
Managing Deal Risks in a Challenging Regulatory Environment: Strategies and Deal Terms With antitrust and other regulators scrutinizing mergers more closely, it is crucial for companies to negotiate terms to mitigate and...more
To understand the litigation and regulatory risks that are coming in 2024 for private capital, it is helpful to look back briefly on recent events. Arguably, the single most important event over the last 18 months was the...more
As US Antitrust Agencies Double Down on Merger Enforcement Approach, New Deal Strategies Emerge The DOJ and FTC continue to pursue an aggressive merger enforcement agenda with new merger guidelines and filing requirements....more
The outlook for public M&A remains challenging, even if we have now reached a plateau in interest rates. We see two primary areas for opportunity: (i) strategic buyers using the current conditions to accelerate...more
As we approach 2024, the M&A landscape is set to experience more shifts and trends that will redefine how companies approach these transactions, and CEOs are keeping a keen eye. n this volatile post-pandemic era...more
The healthcare industry is no stranger to mergers and acquisitions (M&A). Over the years, consolidation has played a significant role in reshaping the healthcare landscape, driven by factors such as regulatory changes,...more